Connect with us

Government

COVID-19’s “Inconsistent Nature” Confuses Us All

COVID-19’s "Inconsistent Nature" Confuses Us All

Published

on

COVID-19's "Inconsistent Nature" Confuses Us All Tyler Durden Mon, 07/13/2020 - 19:05

Authored by Bruce Wilds via Advancing Time blog,

As time goes by covid-19 has proven not to be the hammer or tsunami we feared. It has not taken the large number of lives many experts predicted but it has brought the economy to its knees. It now seems covid-19 is just a deadly bug that will probably with us for some time. Not only has it spread slower than we were told it would but the fatality rate is far lower than many "experts" predicted. Still, this inconsistent beast holds society confused and paralyzed with fear.

The article below is an effort to give this subject some context and frame of reference.

Covid-19 Has Confused Us All

Over time answers have begun to emerge as to the extent covid-19 will have to impact our lives in coming years, however, the truth is being diluted and held hostage by politics. Because I live in a rather conservative area my views may be a bit skewed when it comes to how other Americans see the government's role in handling the pandemic.

Interestingly, it is mainstream media that is largely responsible for banging the drums of fear by speculating the worst is yet to come. Mainstream media appears to be going out of its way to weaponize covid-19 it an effort to demonize Trump and paint his administration as a failure. One theory is that democrats and other big-spending politicians are using all the fear-mongering as a way to  push a massive stimulus package through with little resistance. This is a very troubling development for those of us that expect our government to be at least somewhat responsible and to consider how its actions will impact society.

Early on I pointed out the "need to know more and collect real information" was crucial to creating a plan that would minimize the damage covid-19 posed. That need still exists. When the virus first appeared, the projection below was written based on the lower edge of what the experts were touting as expected percentages of infection. No wonder people became fearful.

We are all like frogs in a pot of water and the water temperature is slowly rising.

If predictions are correct, I see a giant catastrophe ahead. In a city of 300 hundred thousand people, let's do some numbers. They est. 40% to 80% of people may get this bug. Of those American health officials say as many as 20% may need to be hospitalized, some for months.

Going with a 50% catch rate, roughly 150,000 people will get infected in my area.

With only a 10% hospitalization rate it would come to 15,000

We sure don't have the beds in my area to handle such a surge. Note, this is 5% of the population.

In this case, It's not just about how many people may die but the fact that simply

caring for so many very sick people creates a massive problem!

While it is true we should error to the side of caution when dealing with a new pandemic, the problem is that as this unfolded, not only can we not trust the numbers because of fraud and inconsistent testing from one area to another but when important facts or a shred of truth does emerge it is rapidly mucked up when dropped into this data. Adding to the confusion and fear-mongering flowing from the mainstream media is the fact frustrated Americans confronted with a resurgence of the scourge are facing long lines at testing sites in the summer heat or are getting turned away. Some people are having to wait before receiving a diagnosis. Not only are some test sites running out of kits, but labs are also reporting shortages of materials and workers to process the swabs.

The total failure of Governments across the world to lead us through this mess confirms a bleak future for mankind going forward. One critic of  how this has been handled is Ron Paul, a physician that served as the U.S. Representative for Texas's 22nd congressional district from 1976 to 1977 and again from 1979 to 1985 recently wrote an article in which he questioned whether the covid-19 spike in Texas was fake news. He contends Texas Governor Greg Abbott's executive order mandating the wearing of face masks both indoors or outdoors across the state is a violation of the civil liberties of all Texans.

Will History View Fauci As A Hero Or Goat?

Paul argues the executive order is based on inaccurate information about a “rise” in Covid cases due to the Texas State Department of Health Services changing the definition of what constitutes a “Covid case” to a ridiculous levelPaul writes, In a Commissioners Court hearing for Collin County on May 18th, it was revealed that while previously the determination of a Covid “case” was a confirmed test result, the definition was suddenly changed to count “probable” cases as “cases.” This discounts the fact that many people will already carry some natural immunity to covid-19 making them far less likely to catch it.

The policy adopted by Sweden differs greatly from that of other countries. The Swedes have settled on a more traditionalist approach that avoided a full-scale lock-down and has allowed people to maintain their personal freedom even amid this global pandemic. Sweden pursued a course they felt was sustainable and would save as many lives as possible in the long run. While Sweden’s fatality rate is higher than some and lower than others. (Sweden has 543 deaths per million this translates into roughly 1 death in every 2,000 people.) As in other countries, the vast majority of Swedish fatalities have been among people 70 years and older with underlying health conditions.

By settling on a policy, that keeps the economy running, preserves an atmosphere of normality, and exposes its young, low-risk people to the infection, Sweden is moving its population closer towards the ultimate goal of achieving “herd immunity.” Some people think Sweden is very close to reaching the point where the majority of people have developed antibodies that will help to fend-off similar sars-covid infections in the future. This would ensure that future outbreaks will be less disruptive and less lethal. It must be noted that even The Herd Immunity Threshold (“HIT”) is still being debated.

The reason everyone was so scared about covid-19 originally was because after the lock-down in China it was hyped as a completely new deadly virus with no known cure or natural protection. That has turned out to be false but has been promoted by Fauci and many others. This has resulted in vast destruction to the US economy, an explosion in our national debt, an unprecedented spike in unemployment, and the destruction of tens of millions of small businesses. As we look back most people will realize the error we have made by shutting down a $21 trillion economy and ordering 340 million people into quarantine because a small number of people may die.

All this means is the subject of a "covid future" has a lot of parts that we have yet to face. Successfully balancing the damage to the economy and the mess it makes of our lives with health issues is a difficult act. It includes the complications, health issues, and other negative outcomes arising from covid and all the ways that it can affect you even if it doesn’t actually kill you. It includes whether schools should be reopened, whether it is safe to fly, and if governments are abusing our rights when ordering people about claiming it is for the greater good. Expect the confusion to continue but rest assured that through all this, those making the rules and at the top of the food chain will be sure to remain unscathed.

Read More

Continue Reading

Government

Monkeypox cases are rising. Should we be worried?

The World Health Organization has said the current outbreak of monkeypox is the largest ever recorded outside sub-Saharan
The post Monkeypox cases are…

Published

on

The World Health Organization has said the current outbreak of monkeypox is the largest ever recorded outside sub-Saharan Africa, with cases rising above the 100-mark a few days ago and the UK top of the table with 56 as of yesterday.

Top of the list of concerns is how the virus – which does not spread easily between humans and requires skin-to-skin contact – is spreading so quickly in so many countries in Europe, the Americas and Australia where the disease is not endemic.

There is speculation that monkeypox may be being spread between sexual partners, even though it is not normally considered a sexually-transmitted infection. Thankfully, there have been no deaths reported so far, although the WHO notes monkeypox has a fatality rate of between 3% and 6%.

While health authorities are on alert, the WHO said it thinks the outbreak can be contained and that the overall risk to the population remains low. It also stressed there is no evidence that a viral mutation is responsible for the unusual pattern of infections.

Monkeypox is considered less likely to mutate quickly because it is a DNA virus rather than an RNA virus like influenza or COVID-19.

Several countries including Belgium and the UK are already advising a three-week quarantine period for anyone who contracts the virus and their close contacts.

The increasing case numbers in the current monkeypox outbreak are certainly concerning,” commented Dr Charlotte Hammer, an expert in emerging infectious diseases based at the University of Cambridge in the UK.

“It is very unusual to see community transmission in Europe – previous monkeypox cases have been in returning travellers with limited ongoing spread. However, based on the number of cases that were already discovered across Europe and the UK in the previous days, it is not unexpected that additional cases are now being and will be found, especially with the contact tracing that is now happening.”

Vaccines and drugs are available

Meanwhile, attention is now being turned to other measures to control the outbreak, including the use of vaccines against smallpox – a related virus – in a ‘ring vaccination’ approach designed to control the spread among contacts.

Vaccines used during the smallpox eradication programme can provide around 85% protection against monkeypox, according to the WHO, which notes that one newer vaccine – Bavarian Nordic’s Jyneos – has been approved by the FDA for prevention against both viruses.

There’s also a licensed antiviral drug for monkeypox. SIGA Technologies’ oral drug Tpoxx (tecovirimat) is approved for smallpox, monkeypox and cowpox in Europe, and in the US and Canada for smallpox, although it can be used off-label for the other disease. The US FDA also approved a new intravenous form of the drug last week.

The WHO says there is no need for widespread vaccination, as other control measures like isolation of patients should be enough to curb the spread and in any case supplies of vaccines are limited.

Monkeypox causes symptoms similar to but milder than smallpox, typically beginning with fever, headache, muscle aches and exhaustion. It is transmitted to people from various wild animals, such as rodents and primates, and is usually a self-limited disease with symptoms lasting from two to four weeks.

In 2003, the US experienced an outbreak of monkeypox, which was the first time human monkeypox was reported outside of Africa. The Centers for Disease Control and Prevention (CDC) is making some Jyneos vaccine reserves available for close contact inoculations, including healthcare workers tending to patients.

The UK Health Security Agency (UKHSA) said yesterday it had identified 36 additional cases of monkeypox in England, and that vaccination of high-risk contacts of cases is already underway.

“A notable proportion of recent cases in the UK and Europe have been found in gay and bisexual men so we are particularly encouraging these men to be alert to the symptoms,” said the agency’s chief medical advisor Dr Susan Hopkins.

“Because the virus spreads through close contact, we are urging everyone to be aware of any unusual rashes or lesions and to contact a sexual health service if they have any symptoms.”

The post Monkeypox cases are rising. Should we be worried? appeared first on .

Read More

Continue Reading

International

UK’s Johnson Urges Talks As Unions Threaten “Biggest Rail Strike In Modern History”

UK’s Johnson Urges Talks As Unions Threaten "Biggest Rail Strike In Modern History"

Authored by Alexander Zhang via The Epoch Times,

British…

Published

on

UK's Johnson Urges Talks As Unions Threaten "Biggest Rail Strike In Modern History"

Authored by Alexander Zhang via The Epoch Times,

British Prime Minister Boris Johnson has urged rail unions to talk to the government before causing “irreparable damage” with strike action.

The National Union of Rail, Maritime, and Transport Workers (RMT) is holding a ballot of its 40,000 members on plans to strike over jobs, pay, and conditions. The ballot is set to close on Tuesday, and the union has claimed that a yes vote could lead to “the biggest rail strike in modern history.”

Another union, the Transport Salaried Staffs’ Association (TSSA), has also warned of a “summer of discontent” with similar action on the way unless pay disputes are resolved.

The prime minister’s official spokesman said on Monday:

“Railways are going through difficult times with passenger numbers down. We need to make sure they’re fit for the future.”

He said the government wants “a fair deal for staff, for passengers, and taxpayers” so that “money isn’t taken away from other essential services” such as the National Health Service.

“The prime minister is firmly of the view that unions should talk to the government before causing irreparable damage to our railways—strikes should be the last resort not the first,” he added.

Transport Secretary Grant Shapps told The Sunday Telegraph that ministers are looking at drawing up laws which would make industrial action illegal unless a certain number of staff are working.

Shapps said the government hopes the unions will “wake up and smell the coffee” and suggested that strikes could put more people off rail travel.

He also accused unions of going straight to industrial action rather than using it as a last resort, adding that railways were already on “financial life support” because of the CCP (Chinese Communist Party) virus pandemic.

Referring to a pledge in the Conservative Party’s 2019 election manifesto, which promised minimum services during rail strikes, he said:

“We had a pledge in there about minimum service levels. If they really got to that point then minimum service levels would be a way to work towards protecting those freight routes and those sorts of things.”

Unions have reacted to the threat with anger.

RMT General Secretary Mick Lynch said, “Any attempt by Grant Shapps to make effective strike action illegal on the railways will be met with the fiercest resistance from RMT and the wider trade union movement.”

He said the government needs to “focus all their efforts on finding a just settlement” to the rail dispute rather than “attack the democratic rights of working people.”

Tyler Durden Tue, 05/24/2022 - 02:00

Read More

Continue Reading

Government

CytoDyn Inc (OTCMKTS: CYDY) On the Comeback Trail (HIV Leronlimab Update)

CytoDyn Inc (OTCMKTS: CYDY) continues to move steadily higher in recent trading since hitting lows of $0.231 after the FDA placed a partial clinical hold…

Published

on

CytoDyn Inc (OTCMKTS: CYDY) continues to move steadily higher in recent trading since hitting lows of $0.231 after the FDA placed a partial clinical hold on the Company’s HIV program and a full clinical hold on its COVID-19 program in the United States. CYDY was one of the biggest runners of 2020 skyrocketing from pennies to $10 per share and MIcrocapdaily covered the stock regularly back in those exciting times. Since than CYDY has been downward bound, first suffering from the Citron short attack and more recently the March 30 drop after the FDA hold. Further, CytoDyn elected to pause its Brazil COVID-19 trials pending results from its previously scheduled data safety monitoring committee meeting and is in the process of reevaluating the timing of its HIV BLA resubmission. CYDY saw further declines after the Company’s CEO and registered public accounting firm, Warren Averett LLC, both resigned. 

On May 23 CYDY reached a non-cash settlement with its former Chief Medical Officer, Dr. Richard Pestell. The Company will release to Dr. Pestell 8.3 million shares of CYDY held in escrow, transfer to Dr. Pestell the assets acquired from ProstaGene LLC and subsequently written-off by the Company and issue a warrant at an exercise price of $0.37 per share to Dr. Pestell for seven million shares of the Company’s common stock. Dr. Pestell and the Company are also exploring ways in which Dr. Pestell can reengage with the Company to help realize Leronlimab’s full potential in oncology. This is an important step forward for CytoDyn as any potential suitor would want the current management to clear the deck of lawsuits before initiating a buyout or partnership. Also, an all-stock settlement shows a lot of faith in the Company from Dr. Pestell who make come back. At this point Cytodyn must find a sponsor or partner to get Leronmilab back on track for HIV. 

The underlying science of Leronmilab has not changed; leronlimab has demonstrated significant potential to attack a number of diseases including cancer, and HIV.  Considering how fast CYDY dropped the bounce potential here is significant and when CYDY does make a definitive move northbound the stock could make rapid gains in a very shorty time period. Management remains hopeful the FDA will review the case and stop the hold of Leronlimab. 

Sign Up now for our 100% FREE Penny Stock Newsletter

CytoDyn Inc (OTCMKTS: CYDY) is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes. CytoDyn is studying leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions. 

In January Cytodyn reported positive results from the 350 mg weekly dose of its Phase 2 NASH clinical trial. The trial was conducted in two parts. Part 1 compared a 700 mg weekly dose and placebo in a double-blind randomized manner and Part 2 evaluated a 350 mg weekly dose as an open label study compared to the same placebo blinded arm. Results of the topline report will be announced when available.  

The pre-clinical and clinical development of PRO 140 was led by Progenics Pharmaceuticals, Inc. through 2011. The Company acquired the asset from Progenics in October 2012. In February 2018, CYDY announced it had met the primary endpoint in its Phase 3 trial for leronlimab as a combination therapy with HAART for highly treatment-experienced HIV patients and first submitted the non-clinical portion of the Company’s Biologics License Application (“BLA”) to the FDA in March 2019.  

To Find out the inside Scoop on CYDY Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

CYDY

Cytodyns current business strategy is to resubmit its BLA to the FDA as soon as possible, to finalize with the FDA our submitted protocol for a pivotal Phase 3 clinical trial with leronlimab as a monotherapy for HIV patients, to seek emergency use authorization and approval for leronlimab as a potential therapeutic benefit for COVID-19 patients with mild-to-moderate, severe-to-critical, and long-haulers indications in the U.S., Brazil, and other countries, to advance the Company’s clinical trials with leronlimab for various forms of cancer, including, among others, the Phase 2 clinical trial for metastatic triple-negative breast cancer and Phase 2 basket trial for 22 solid tumor cancers, to complete the Phase 2 trial for liver fibrosis associated with nonalcoholic steatohepatitis (“NASH”), and to explore other cancer and immunologic indications for leronlimab.  

On May 23 CYDY announced it has reached a non-cash settlement with its former Chief Medical Officer, Dr. Richard Pestell, concerning an ongoing legal dispute related to his former employment with the Company. 

Under the terms of the agreement, the parties will release each other of all claims, and the Company will release to Dr. Pestell 8.3 million shares of the Company’s common stock held in escrow, transfer to Dr. Pestell the assets acquired from ProstaGene LLC and subsequently written-off by the Company and issue a warrant at an exercise price of $0.37 per share to Dr. Pestell for seven million shares of the Company’s common stock. Dr. Pestell and the Company are also exploring ways in which Dr. Pestell can reengage with the Company to help realize leronlimab’s full potential in oncology. CytoDyn regrets Dr. Pestell’s departure from the Company and the subsequent public statements made by its former CEO about Dr. Pestell. 

Dr. Pestell has published more than 600 works, is the most frequently cited scientist in the field of cell-cycle control and was appointed an Officer of the Order of Australia in the 2019 Queen’s Birthday Honours for distinguished service to medicine and medical education. He has served on editorial boards of six journals, was the Director of two NCI-designated Cancer Centers and has founded several biotechnology companies. He serves as an advisor and reviewer for a number of domestic and international research centers, including NCI cancer centers. 

For More on CYDY Subscribe Right Now!

Currently trading at a $226 million market valuation CYDY is an SEC filer and is fully reporting OTCQB. The Company has close to $100 million in assets and about that in debt. At current price levels CYDY is worth a close look; CYDY was one of the biggest runners of 2020 skyrocketing from pennies to $10 per share. While there are plenty of ricks not to mention the CEO and accounting firm resigning CYDY is moving northbound now and looks to be coming back. The underlying science has not changed; Leronlimab has demonstrated significant potential to attack a number of diseases including cancer and HIV.  Considering how fast CYDY dropped the bounce potential here is significant and when CYDY does make a definitive move northbound the stock could make rapid gains in a very shorty time period. Management remains hopeful the FDA will review the case and stop the hold of Leronlimab. We will be updating on CYDY when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CYDY.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in CYDY either long or short and we have not been compensated for this article.

The post CytoDyn Inc (OTCMKTS: CYDY) On the Comeback Trail (HIV Leronlimab Update) first appeared on Micro Cap Daily.

Read More

Continue Reading

Trending